"beta 2-Glycoprotein I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
| Descriptor ID |
D053482
|
| MeSH Number(s) |
D12.776.124.117 D12.776.395.195
|
| Concept/Terms |
beta 2-Glycoprotein I- beta 2-Glycoprotein I
- beta 2 Glycoprotein I
- Apo H
- Endothelial Cell-Viability Maintaining Factor
- Endothelial Cell Viability Maintaining Factor
- beta(2)GPI
- beta2-Glycoprotein I
- beta2 Glycoprotein I
- EC-VMFa
- EC VMFa
- Anticardiolipin Cofactor
- Cofactor, Anticardiolipin
- Apolipoprotein H
|
Below are MeSH descriptors whose meaning is more general than "beta 2-Glycoprotein I".
Below are MeSH descriptors whose meaning is more specific than "beta 2-Glycoprotein I".
This graph shows the total number of publications written about "beta 2-Glycoprotein I" by people in this website by year, and whether "beta 2-Glycoprotein I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "beta 2-Glycoprotein I" by people in Profiles.
-
The Role of Antiphospholipid Antibodies in COVID-19. Curr Rheumatol Rep. 2021 07 14; 23(9):72.
-
Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep. 2021 07 03; 23(8):65.
-
Reality Check on Antiphospholipid Antibodies in COVID-19-Associated Coagulopathy. Arthritis Rheumatol. 2021 01; 73(1):173-174.
-
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Front Immunol. 2020; 11:584241.
-
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):754-759.
-
Antiphospholipid antibodies in patients with COVID-19: A relevant observation? J Thromb Haemost. 2020 09; 18(9):2191-2201.
-
Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020 12; 79(12):1661-1663.
-
Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Front Immunol. 2019; 10:1948.
-
Role of TLR-4 in anti-ß2-glycoprotein I-induced activation of peritoneal macrophages and vascular endothelial cells in mice. Mol Med Rep. 2019 May; 19(5):4353-4363.
-
Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. Front Immunol. 2019; 10:460.